Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TUSC8 is a long non-coding RNA identified as a tumor suppressor candidate and is significantly down-regulated in a range of human cancers, including breast cancer, osteosarcoma, and cervical cancer. It mediates anti-tumor effects predominantly by acting as a competitive endogenous RNA that binds and sequesters oncogenic microRNAs, thereby promoting the expression of a range of tumor suppressor proteins (such as MYLIP, EHD2, and PTEN). The reduction of TUSC8 expression is associated with increased tumor cell proliferation, migration, invasion, and EMT, as well as poorer clinical outcomes. While TUSC8 itself is not a typical druggable target, it is studied as a prognostic biomarker and as a potential indirect therapeutic target through modulation of its regulatory axis in cancer signaling.
Not applicable for drugs, as TUSC8 is not a direct pharmacological target. Functionally, it acts by sequestering oncogenic microRNAs, thereby regulating expression of tumor suppressors or oncogenes (e.g., MYLIP, EHD2, PTEN, MDM2)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor suppressor candidate 8 (TUSC8).